| Document |
Document Title |
|
WO/2020/103945A1 |
Disclosed are an oxycodone compound, and an intermediate and a preparation method therefor. Specifically disclosed is a preparation method for a compound represented by formula A9, comprising the following steps: under a protective gas, ...
|
|
WO/2020/105364A1 |
The purpose of the present invention is to provide a non-ionic photo-acid generator which exhibits high photosensitivity to i-rays, excellent compatibility with, and solubility in, a resist solution, and excellent thermal stability. The ...
|
|
WO/2020/103294A1 |
Disclosed are an organic micromolecule light-emitting material and an organic electroluminescent component. The organic micromolecule light-emitting material is produced by coupling a novel acridine donor unit 10H-spiro[acridine-9,2'-ada...
|
|
WO/2020/102576A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/102096A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/102574A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: Formula AA or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.
|
|
WO/2020/081975A1 |
The invention is directed to (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H- dibenzo[de,g]quinoline-10,11-diol for the treatment of diseases mediated by protein misfolding of Cu/Zn Superoxide Dismutase (SOD1) or mediated by astrocyte toxicity aff...
|
|
WO/2020/077217A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases, disorders and conditions.
|
|
WO/2020/075761A1 |
The present invention addresses the problem of providing: an imide derivative which has a high luminous quantum yield and in which concentration quenching is suppressed; a luminous composition containing the same; a luminous thin film; a...
|
|
WO/2020/069179A1 |
The present invention provides a method for chemically modifying a nucleic acid molecule using sulfinate reagents to increase stability in vitro and in vivo. Screening methods for nucleobase modifications that reduce cleavage of a nuclei...
|
|
WO/2020/063760A1 |
Provided is a compound of formula I, their synthesis and their use for treating a SHP2 mediated disorder. More particularly, provided is a pharmaceutical composition comprising the said compound.
|
|
WO/2019/132492A9 |
The present specification relates to a heterocyclic compound represented by chemical formula 1 and an organic light emitting device comprising the same.
|
|
WO/2020/050160A1 |
A hydrogenation catalyst for amide compounds which comprises hydroxyapatite and, fixed thereto, platinum and vanadium, characterized in that 15-80% of the surface of the platinum is covered with vanadium. With the catalyst, it is possibl...
|
|
WO/2020/050729A1 |
The invention relates to a radioisotope-labelled compound of quaternary ammonium salt of a polycyclic aromatic amine with formula I, wherein the wavy line indicates a single bond between the non-nodal carbon atom of a polycyclic aromatic...
|
|
WO/2020/047168A1 |
The present invention is directed towards new chemical entities winch primarily inhibit the human T-type calcium channels and differentially modulate other key ion channels to control cell excitability, and abnormal neuronal activity, pa...
|
|
WO/2020/036329A1 |
The present invention relates to a fluorescent probe for detecting NAD(P)H in mitochondria, and a detection method using same. A probe of the present invention exhibits high selectivity and sensitivity to NAD(P)H and emits strong red flu...
|
|
WO/2020/023391A1 |
The present disclosure provides 1) an enantiomerically purified compound SRR G-1, or a derivative thereof, including specific crystal forms, salts and co-crystals that modulates G protein-coupled estrogen receptor activity, 2) pharmaceut...
|
|
WO/2020/016264A1 |
The present invention relates to compounds of the formula (1) and mixture comprising these compounds, which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which com...
|
|
WO/2020/016233A1 |
The present invention relates to an organic compound of formula (1), suitable for use as a layer material for electronic devices, and it relates to an organic semiconductor layer comprising at least one compound thereof, as well as to an...
|
|
WO/2020/011228A1 |
Antibiotic compounds having both antibiotic and aggregation-induced emission (AIE) characteristics. The compounds comprise an azole antibiotic unit, for example naphthalimide triazole (NT), and an AIE unit, for example triphenylethylene ...
|
|
WO/2020/012842A1 |
The present invention provides a photoelectric conversion element which is capable of improving the afterimage characteristics. This photoelectric conversion element is provided with: a first electrode and a second electrode, which are a...
|
|
WO/2020/010143A1 |
In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein, useful to tre...
|
|
WO/2019/222854A1 |
Described herein is the development of synthetic routes to produce a wide variety of substituted phenanthridines, specifically, multidentate phenanthridine- containing ligand frameworks capable of anchoring to Pt via more than one bindin...
|
|
WO/2019/222103A1 |
The invention is directed to a novel crystalline S-apomorphine hydrochloride hydrate salt.
|
|
WO/2019/203430A1 |
The present invention relates to a novel compound and an organic electroluminescent device comprising same. As the compound according to the present invention is used for an organic material layer of an organic electroluminescent device,...
|
|
WO/2019/201621A1 |
The present invention relates to a compound of Formula (I) wherein Ar1 is selected from substituted or unsubstituted C2 to C36heteroaryl and the group Ar1 is bound to the remaining structure represented by Formula (I) via one of its carb...
|
|
WO/2019/196022A1 |
Disclosed are a 1,8-naphthalimide derivative, a preparation method therefor and a use thereof. The 1,8-naphthalimide derivative of the present invention is relatively easy to prepare, and is an enhanced Cu2+ fluorescent probe, which can ...
|
|
WO/2019/193540A1 |
The invention is directed to substituted heteroaryl derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein A, C, D, L2, L3, R1, R2, R3, R4, R 5, R6, z2, z4, z5, and z6 are as defined herein; or...
|
|
WO/2019/193068A1 |
The present invention relates to a process for the synthesis of a carbon labeled organic compound containing a carbon labeled carboxyl group. The present invention also concerns the use of carbon labeled organic compounds containing a ca...
|
|
WO/2019/183589A1 |
The present disclosure relates generally to eukaryotic initiation factor 2B modulators of formula A, or a pharmaceutically acceptable salt, stereoisomer, or mixture of stereoisomers thereof and methods of making and using thereof.
|
|
WO/2019/182924A1 |
Janus kinases (JAKs) inhibitors have Formula (I).
|
|
WO/2019/183367A1 |
The present disclosure relates to novel compounds including formula (X) and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The prese...
|
|
WO/2019/175897A1 |
The compounds of Formula I is described herein along with their polymorphs, stereoisomers, tautomers, prodrugs, solvates, and pharmaceutically acceptable salts thereof. The compounds described herein, their polymorphs, stereoisomers, tau...
|
|
WO/2019/175117A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controllin...
|
|
WO/2019/178091A1 |
Compounds, compositions and methods are provided for the inhibition of GBP1. The subject inhibitor compounds can act by inhibiting GBP1 alone and/or GBP1 : pro-survival kinase (e.g. serine/threonine-protein kinase pim-1 (PIM1 )) interact...
|
|
WO/2019/170745A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controllin...
|
|
WO/2019/166270A1 |
The invention relates to an organic electronic device comprising at least one electron transport, electron injection or electron generation layer comprising a compound of Formula (I) wherein all positions which are not linked to a -(A)a-...
|
|
WO/2019/166269A1 |
The present invention relates to an organic electronic device comprising, between an anode and a cathode, at least one layer selected from an electron injection layer, an electron transport layer or an electron generation layer, the laye...
|
|
WO/2019/165890A1 |
Provided herein are chiral compounds that exhibit circularly polarized photoluminescence and electroluminescence and electroluminescent devices and circularly polarized fluorescent probes comprising the same.
|
|
WO/2019/158666A1 |
The present invention relates to compounds of Formula (I), wherein R1, R2, R3, R4 and G are as defined herein. The invention further relates to herbicidal compositions which comprise a compound of Formula (I), to their use for controllin...
|
|
WO/2019/154395A1 |
Disclosed are a novel tetrahydroisoquinoline compound, a method for preparing intermediates thereof, a pharmaceutical composition thereof and the use thereof. The tetrahydroisoquinoline compound of the present invention has a good inhibi...
|
|
WO/2019/144888A1 |
The present invention relates to a method for preparing mesaconine and related intermediaries. Specifically, the method for preparing mesaconine of the present invention uses aconitine extracted from the aconitum plant Aconitum soongaric...
|
|
WO/2019/147742A1 |
A pro-fragrance delivery system based on a vitamin scaffold and a fragrant alcohol. The vitamin scaffold may be a vitamer of vitamin B6 or derivatives thereof. The pro-fragrance releases the fragrant alcohol by action of water at neutral...
|
|
WO/2019/144889A1 |
The present invention relates to crystalline forms of mesaconine. Specifically, the present invention relates to crystalline form A, crystalline form B, and crystalline form C of mesaconine and a preparation method therefor. The method c...
|
|
WO/2019/148125A1 |
Provided herein are compounds comprising a three-ring core, such as compounds of Formula (X), Formula (X-A), Formula (X-Ai), Formula (X-B), Formula (X-Bi), Formula (Z), Formula (Z-A), Formula (Z-Ai), Formula (Z-B), Formula (Z-Bi), Formul...
|
|
WO/2019/141673A1 |
A pharmaceutical composition comprising apomorphine (APO) in a solid crystalline form, wherein the solid crystalline form is an APO·palmitic acid cocrystal solid particle crystalline form.
|
|
WO/2019/132483A1 |
The present specification relates to a heterocyclic compound represented by chemical formula 1 and an organic light emitting element comprising the same.
|
|
WO/2019/118855A1 |
The present invention includes compounds, compositions and methods that are useful for preventing or treating certain types of cancer in a subject. In certain embodiments, the compounds comprise estrogen (including estrogen derivatives o...
|
|
WO/2019/100057A1 |
The disclosure provides methods of using certain morphinans of Formula (I) that are partial kappa opioid receptor agonists, weak mu opioid receptor agonists, and partial or weak delta opioid receptor agonists in the treatment of kappa op...
|
|
WO/2019/099457A1 |
Provided herein are benzodioxinone compounds of Formula I that are useful as inhibitors of ACC1 and/or ACC2. The benzodioxinone compounds described herein can be used for treating a disease or disorder associated with aberrant ACC1 and/o...
|
